Directed evolution of a recombinase that excises the provirus of most HIV-1 primary isolates with high specificity

Nature Biotechnology

Volumn 34, Issue 4, 2016, Pages 401-409

  Karpinski, Janet ^a,b   Hauber, Ilona ^b   Chemnitz, Jan ^b   Schäfer, Carola ^b,c   Paszkowski Rogacz, Maciej ^a   Chakraborty, Deboyoti ^a   Beschorner, Niklas ^b   Hofmann Sieber, Helga ^b,c   Lange, Ulrike C ^b,c,d   Grundhoff, Adam ^b,c   Hackmann, Karl ^e   Schrock, Evelin ^e   Abi Ghanem, Josephine ^e   Pisabarro, M Teresa ^e   Surendranath, Vineeth ^f   Schambach, Axel ^g   Lindner, Christoph ^h   Van Lunzen, Jan ^b,c,d   Hauber, Joachim ^b,c   Buchholz, Frank ^a,f  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

^c German Center for Infection Research (DZIF)   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^f MAX PLANCK INSTITUTE OF MOLECULAR CELL BIOLOGY AND GENETICS   (Germany)

^g HANNOVER MEDICAL SCHOOL   (Germany)

^h AGAPLESION Diakonieklinikum Hamburg   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRAL AGENTS; CELLS; CYTOLOGY; VIRUSES;

ANTIRETROVIRALS; CLINICAL APPLICATION; DIRECTED EVOLUTION; HIGH SPECIFICITY; IN-VITRO; INFECTED CELLS; LONG TERMINAL REPEATS;

DISEASES;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BREC1 RECOMBINASE; LENTIVIRUS VECTOR; RECOMBINASE; UNCLASSIFIED DRUG; ANTIVIRUS AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DIRECTED MOLECULAR EVOLUTION; DRUG EFFICACY; DRUG SPECIFICITY; FEMALE; HELA CELL LINE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; IN VIVO STUDY; INTRAHEPATIC DRUG ADMINISTRATION; LONG TERMINAL REPEAT; MALE; MOUSE; MOUSE MODEL; NEWBORN; NONHUMAN; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; PROVIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS STRAIN; ANIMAL; CELL CULTURE; DRUG EFFECTS; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PROCEDURES; VIROLOGY; VIRUS DNA CELL DNA INTERACTION;

ANIMALS; ANTIVIRAL AGENTS; BASE SEQUENCE; CELLS, CULTURED; DIRECTED MOLECULAR EVOLUTION; HIV INFECTIONS; HIV-1; HUMANS; MICE; MOLECULAR SEQUENCE DATA; PROVIRUSES; RECOMBINASES; VIRUS INTEGRATION;

EID: 84963553372     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.3467     Document Type: Article

References (59)

1. Passaes, C.P. & Saez-Cirion, A. HIV cure research: advances and prospects. Virology 454-455, 340-352 (2014).
2. Maartens, G., Celum, C. & Lewin, S.R. HIV infection: epidemiology, pathogenesis, treatment, and prevention. Lancet 384, 258-271 (2014).
3. Fauci, A.S., Marston, H.D. & Folkers, G.K. An HIV cure: feasibility, discovery, and implementation. J. Am. Med. Assoc. 312, 335-336 (2014).
4. Mbonye, U. & Karn, J. Transcriptional control of HIV latency: cellular signaling pathways, epigenetics, happenstance and the hope for a cure. Virology 454-455, 328-339 (2014).
5. Battistini, A. & Sgarbanti, M. HIV-1 latency: an update of molecular mechanisms and therapeutic strategies. Viruses 6, 1715-1758 (2014).
6. Chun, T.W., Davey, R.T. Jr., Engel, D., Lane, H.C. & Fauci, A.S. Re-emergence of HIV after stopping therapy. Nature 401, 874-875 (1999).
7. Akay, C., et al. Antiretroviral drugs induce oxidative stress and neuronal damage in the central nervous system. J. Neurovirol. 20, 39-53 (2014).
8. Richman, D.D. Antiviral drug resistance. Antiviral Res. 71, 117-121 (2006).
9. Pinoges, L., et al. Risk factors and mortality associated with resistance to first-line antiretroviral therapy: multicentric cross-sectional and longitudinal analyses. J. Acquir. Immune Defic. Syndr. 68, 527-535 (2015).
10. Petoumenos, K., et al. D:A:D Study Group. Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. J. Int. AIDS Soc. 15, 17426 (2012).
11. Nachega, J.B., et al. HIV treatment adherence, drug resistance, virologic failure: evolving concepts. Infect. Disord. Drug Targets 11, 167-174 (2011).
12. Rappold, M., et al. Treatment modification in HIV-Infected individuals starting antiretroviral therapy between 2011 and 2014. J. Int. AIDS Soc. 17 (suppl. 3), 19768 (2014).
13. Schackman, B.R., et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med. Care 44, 990-997 (2006).
14. Beltran, L.M., et al. Influence of immune activation and inflammatory response on cardiovascular risk associated with the human immunodeficiency virus. Vasc. Health Risk Manag. 11, 35-48 (2015).
15. Sarkar, I., Hauber, I., Hauber, J. & Buchholz, F. HIV-1 proviral DNA excision using an evolved recombinase. Science 316, 1912-1915 (2007).
16. Qu, X., et al. Zinc-finger-nucleases mediate specific and efficient excision of HIV-1 proviral DNA from infected and latently infected human T cells. Nucleic Acids Res. 41, 7771-7782 (2013).
17. Ebina, H., Misawa, N., Kanemura, Y. & Koyanagi, Y. Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Sci. Rep. 3, 2510 (2013).
18. Hu, W., et al. RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. Proc. Natl. Acad. Sci. USA 111, 11461-11466 (2014).
19. Surendranath, V., Chusainow, J., Hauber, J., Buchholz, F. & Habermann, B.H. SeLOX-a locus of recombination site search tool for the detection and directed evolution of site-specific recombination systems. Nucleic Acids Res. 38, W293-W298 (2010).
20. Buchholz, F. & Stewart, A.F. Alteration of Cre recombinase site specificity by substrate-linked protein evolution. Nat. Biotechnol. 19, 1047-1052 (2001).
21. Santoro, S.W. & Schultz, P.G. Directed evolution of the site specificity of Cre recombinase. Proc. Natl. Acad. Sci. USA 99, 4185-4190 (2002).
22. Sauer, B. & McDermott, J. DNA recombination with a heterospecific Cre homolog identified from comparison of the pac-c1 regions of P1-related phages. Nucleic Acids Res. 32, 6086-6095 (2004).
23. Karimova, M., et al. Vika/vox, a novel efficient and specific Cre/loxP-like site-specific recombination system. Nucleic Acids Res. 41, e37 (2013).
24. Buchholz, F. & Hauber, J. In vitro evolution and analysis of HIV-1 LTR-specific recombinases. Methods 53, 102-109 (2011).
25. Abi-Ghanem, J., et al. Engineering of a target site-specific recombinase by a combined evolution- and structure-guided approach. Nucleic Acids Res. 41, 2394-2403 (2013).
26. Van Duyne, G.D. A structural view of cre-loxP site-specific recombination. Annu. Rev. Biophys. Biomol. Struct. 30, 87-104 (2001).
27. Ennifar, E., Meyer, J.E., Buchholz, F., Stewart, A.F. & Suck, D. Crystal structure of a wild-type Cre recombinase-loxP synapse reveals a novel spacer conformation suggesting an alternative mechanism for DNA cleavage activation. Nucleic Acids Res. 31, 5449-5460 (2003).
28. Suerth, J.D., Maetzig, T., Galla, M., Baum, C. & Schambach, A. Self-inactivating alpharetroviral vectors with a split-packaging design. J. Virol. 84, 6626-6635 (2010).
29. Hauber, I., et al. Highly significant antiviral activity of HIV-1 LTR-specific tre-recombinase in humanized mice. PLoS Pathog. 9, e1003587 (2013).
30. Perez, E.E., et al. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat. Biotechnol. 26, 808-816 (2008).
31. Holt, N., et al. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat. Biotechnol. 28, 839-847 (2010).
32. Whitney, J.B., et al. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature 512, 74-77 (2014).
33. Taylor, B.S., Sobieszczyk, M.E., McCutchan, F.E. & Hammer, S.M. The challenge of HIV-1 subtype diversity. N. Engl. J. Med. 358, 1590-1602 (2008).
34. Crowell, T.A., et al. Hospitalization rates and reasons among HIV elite controllers and persons with medically controlled HIV infection. J. Infect. Dis. 211, 1692-1702 (2015).
35. Suzuki, E. & Nakayama, M. VCre/VloxP and SCre/SloxP: new site-specific recombination systems for genome engineering. Nucleic Acids Res. 39, e49 (2011).
36. Tebas, P., et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N. Engl. J. Med. 370, 901-910 (2014).
37. Pattanayak, V., Ramirez, C.L., Joung, J.K. & Liu, D.R. Revealing off-target cleavage specificities of zinc-finger nucleases by in vitro selection. Nat. Methods 8, 765-770 (2011).
38. Gabriel, R., et al. An unbiased genome-wide analysis of zinc-finger nuclease specificity. Nat. Biotechnol. 29, 816-823 (2011).
39. Tsai, S.Q., et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat. Biotechnol. 33, 187-197 (2015).
40. Wang, X., et al. Unbiased detection of off-target cleavage by CRISPR-Cas9 and TALENs using integrase-defective lentiviral vectors. Nat. Biotechnol. 33, 175-178 (2015).
41. Kim, H. & Kim, J.S. A guide to genome engineering with programmable nucleases. Nat. Rev. Genet. 15, 321-334 (2014).
42. Josefsson, L., et al. Majority of CD4+ T cells from peripheral blood of HIV-1-infected individuals contain only one HIV DNA molecule. Proc. Natl. Acad. Sci. USA 108, 11199-11204 (2011).
43. Josefsson, L., et al. Single cell analysis of lymph node tissue from HIV-1 infected patients reveals that the majority of CD4+ T-cells contain one HIV-1 DNA molecule. PLoS Pathog. 9, e1003432 (2013).
44. Ringrose, L., Chabanis, S., Angrand, P.O., Woodroofe, C. & Stewart, A.F. Quantitative comparison of DNA looping in vitro and in vivo: chromatin increases effective DNA flexibility at short distances. EMBO J. 18, 6630-6641 (1999).
45. Santarosa, M. & Ashworth, A. Haploinsufficiency for tumour suppressor genes: when you dont need to go all the way. Biochim. Biophys. Acta 1654, 105-122 (2004).
46. Archin, N.M., et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487, 482-485 (2012).
47. Caskey, M., et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522, 487-491 (2015).
48. Blankson, J.N., Siliciano, J.D. & Siliciano, R.F. Finding a cure for human immunodeficiency virus-1 infection. Infect. Dis. Clin. North Am. 28, 633-650 (2014).
49. Scherer, L.J. & Rossi, J.J. Ex vivo gene therapy for HIV-1 treatment. Hum. Mol. Genet. 20, R100-R107 (2011).
50. Herrera-Carrillo, E. & Berkhout, B. Bone Marrow Gene Therapy for HIV/AIDS. Viruses 7, 3910-3936 (2015).
51. Deeks, S.G. HIV: Shock and kill. Nature 487, 439-440 (2012).
52. Katlama, C., et al. Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet 381, 2109-2117 (2013).
53. Munch, R.C., et al. Off-target-free gene delivery by affinity-purified receptor-targeted viral vectors. Nat. Commun. 6, 6246 (2015).
54. Chomont, N., et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat. Med. 15, 893-900 (2009).
55. Anastassiadis, K., et al. Dre recombinase, like Cre, is a highly efficient site-specific recombinase in E. coli, mammalian cells and mice. Dis. Model. Mech. 2, 508-515 (2009).
56. Langmead, B. & Salzberg, S.L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357-359 (2012).
57. Li, H., et al. 1000 Genome Project Data Processing Subgroup. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078-2079 (2009).
58. Prufer, K., et al. PatMaN: rapid alignment of short sequences to large databases. Bioinformatics 24, 1530-1531 (2008).
59. Waterhouse, A.M., Procter, J.B., Martin, D.M.A., Clamp, M. & Barton, G.J. Jalview Version 2-a multiple sequence alignment editor and analysis workbench. Bioinformatics 25, 1189-1191 (2009).